Arch Biopartners Inc.
3 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| LSALT Peptide for Prevention or Attenuation of Acute Kidney Injury (AKI) in Patients Undergoing On-Pump Cardiac Surgery (NCT05879432) | Arch Biopartners Inc. | 2024-03-08 |
| LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19) (NCT04402957) | Arch Biopartners Inc. | 2020-10-14 |
| A Phase I Study to Evaluate LSALT Peptide (NCT03772678) | Arch Biopartners Inc. | 2019-06-27 |
Track Arch Biopartners Inc. automatically
Every clearance here is in the API, with alerts when new ones post.